Floatz logo

12 assets in Urinary Bladder Small Cell Neuroendocrine Carcinoma

Therapeutic assets addressing Urinary Bladder Small Cell Neuroendocrine Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cabozantinib
Urinary Bladder Small Cell Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (60)
Nivolumab
Urinary Bladder Small Cell Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (60)
Ipilimumab
Urinary Bladder Small Cell Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2B (59)
Lurbinectedin
Urinary Bladder Small Cell Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2CCC (53)
[203Pb]Pb-MP0712
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Molecular Partners AGP1/2CCC (48)
[212pb]pb-mp0712
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Molecular Partners AGP1/2CCC (48)
Avelumab
Urinary Bladder Small Cell Neuroendocrine Carcinoma
National Cancer Institute (NCI)P2CCC (48)
Carboplatin
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Cis-Diamminedichloroplatinum Ii
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Docetaxel
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Etoposide
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Pembrolizumab
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)